Pharma Market Research

Ethical Pharmaceuticals Market Research Reports

To order sections of the reports, contact  Dr.Zadorin Eugene, PhD

 

Hepatitis B Drug Market Forecasts by Country

This model contains ten-year commercial forecasts for hepatitis B drug sales by class, molecule and brand for the US, Japan, France, Germany, Italy, Spain, UK and Turkey.

Reasons to Purchase

Understand the changing market dynamics of hepatitis B drugs, and success factors for leading brands….

$15200.00

HIV Antiretrovirals Market Forecasts

In 2009, HIV antiretrovirals sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10….

$15200.00

Antihormonal Therapy Market Forecasts

Antihormonal cancer therapies are used predominantly in the treatment of breast and prostate cancers. The high incidence of these tumors translates into a significant commercial potential for drug developers….

 

$15200.00

Cytotoxic Therapies: Drug Launches in Rare Indications to Offset Sales Decline

 

Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%….

 

$15200.00

Antihormonal Cancer Therapies: Leading Brands Strive to Minimize Generic Sales Erosion

 

Antihormonal cancer therapies are used predominantly in the treatment of breast and prostate cancers. The high incidence of these tumors translates into a significant commercial potential for drug developers….

$15200.00

Gastric Cancer

 

Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric cancer patients. There is an urgent need for more effective therapies to improve survival rates in patients presenting with both localized and advanced disease….

 

$15200.00

Spondyloarthropathies: Disease Perception Limits Market

 

Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form of inflammatory arthritis associated with psoriasis, whilst ankylosing spondylitis causes arthritis of the spine and sacroiliac joints….

$15200.00

Commercial Insight: Cardiovascular and Metabolic Market Overview

Innovative Development Pipeline Provides Limited Growth

As Primary Care Markets Become Generic

 

Introduction

 

Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2018. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0….

$15200.00

Pharmaceutical Licensing Overview: Risk-Aversion Breeds Creativity as Externalization Intensifies

 

Big Pharma continues to restructure its internal R&D departments as part of widespread cost-cutting measures to help reduce the impact of the impending 2011 patent cliff. To fill pipeline voids with new products, companies continue to make acquisitions and form partnerships with small pharma, biotech companies and academia, although the relationships between each are becoming increasingly dynamic….

$15200.00

The 2011 Top Ten World’s Leading Pharmaceutical Companies

 

A thought-provoking report on performance, capabilities, goals and strategies of the major competitors in the worldwide pharmaceutical market. The report is designed to provide the pharmaceutical industry executives with strategically significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs….

$13200.00

Product Profiles: Prostate Cancer – Recent approvals create competitive environment for new market entrants

 

Introduction

 

Androgen deprivation therapies (ADTs) are the main treatment type for hormone-sensitive prostate cancer. As the disease is hormonally fuelled, chemical castration provides adequate disease control for a number of years….

$11400.00

Asia Pacific Pharmaceutical Market: Strategic Assessments of Leading Suppliers

 

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Asia Pacific pharmaceutical market.

 

The report provides a worldwide strategic overview of the pharmaceutical market, including:

 

 

$9800.00

European Pharmaceutical Market: Strategic Assessments of Leading Suppliers

 

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market.

 

The report provides a worldwide strategic overview of the pharmaceutical market, including:

 

 

$9800.00

North American Pharmaceutical Market: Strategic Assessments of Leading Suppliers

 

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the North American pharmaceutical market.

 

The report provides a worldwide strategic overview of the pharmaceutical market, including:

 

 

$9800.00

Global Cardiovascular Drug Market: Strategic Assessments of Leading Suppliers

 

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Cardiovascular Drug Market.

 

The report provides a worldwide strategic overview of the pharmaceutical market, including:

 

 

$9800.00

Global CNS Drug Market: Strategic Assessments of Leading Suppliers

 

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global CNS Drug Market.

 

The report provides a worldwide strategic overview of the pharmaceutical market, including:

 

 

$9800.00

Global Infectious Disease Drug Market: Strategic Assessments of Leading Suppliers

 

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Infectious Disease Drug Market.

 

The report provides a worldwide strategic overview of the pharmaceutical market, including:

 

 

$9800.00

Global Oncology Drug Market: Strategic Assessments of Leading Suppliers

 

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Oncology Drug Market.

 

The report provides a worldwide strategic overview of the pharmaceutical market, including:

 

 

$9800.00

 

Pharmaceutical M&A in Asia-Pacific: India and China Drive Regional Activity, but Japan Dominates High Value Transactions

Expanding healthcare coverage in emerging Asia-Pacific markets, rapid economic growth and burgeoning middle classes are attracting foreign M&A as companies attempt to offset future losses from the looming threat of the 2011 “patent cliff” and slowing growth in major developed markets. As these markets expand, consolidation of the domestic industry is also driving M&A in the Asia-Pacific region….

$7600.00

Mapping the Healthcare Landscape – Bringing Pharmaceuticals into Focus

 

Introduction

Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, with diversification away from pharmaceuticals into other healthcare sectors one avenue under consideration.

$7600.00

Rx-to-OTC Strategies: Maximizing Commercial Potential

 

With the growing cost of developing novel drugs, combined with the declining trend in the number of drugs gaining regulatory approval, the use of lifecycle management is playing a more important role in the increasingly cost-conscious pharma industry. Rx-to-OTC switching strategy is being increasingly employed to either enhance existing franchise revenues or protect branded revenues from generic competition….

$5700.00

Inflammatory Bowel Disease: Incidence Prevalence, Early Diagnosis and Improved Survival

 

Introduction Since the 1950s, the incidence of inflammatory bowel disease has substantially increased worldwide. However, over the last two decades, incidence of IBD has started to stabilize in the West suggesting a peak in incidence has been reached….

$5700.00

Human Genome Sciences

 

Introduction

This analysis examines the historical and forecast performance for Human Genome Sciences in the prescription pharmaceutical sector. The profile encompasses key product analysis and forecasts, pipeline assessment, and evaluation of company strategy and financial performance over a 6-year period.

$5700.00

Amgen

 

Introduction

This analysis examines the historical and forecast performance for Amgen in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

$5700.00

Johnson & Johnson

Introduction

This analysis examines the historical and forecast performance for Johnson & Johnson in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

$5700.00

Established and Emerging Biotech Clusters

 

Introduction

 

There has been widespread interest in establishing geographically focused clusters of biotechnology companies and related organizations. It is important for all stakeholders to understand the capabilities of different clusters across the world….

$4795.00

Back to the Lab! Improving R and D Productivity and Efficiency with LIMS and ELNs

 

Introduction

 

The rigorous R&D processes of pharma and biotech have provided them with a wealth of data, documents and knowledge, but this information is often held in organizational silos, paper laboratory notebooks and disparate IT systems, rendering them virtually useless. Therefore, life sciences companies are implementing LIMS and ELNs to remove the silos and connect R&D groups across the enterprise….

$3995.00

Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of Legal, Productivity, and Quality Control Issues

 

In 2007, due to the impending patent cliff and the consequent need to cut costs, big pharma began for the first time to outsource chemical API manufacturing to China and India. Prior to this, only generic drug companies had manufactured in the two countries….

$3835.00

Immunosuppressants, Organ Transplants, and Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis

 

This report examines treatment protocols evolved over the last ten years. It also appraises novel compounds in development, highlighting potential clinical advances along with analysis of the potential impact of regenerative medicine (stem cells) on the market, with drivers and resistors to market growth….

$3835.00

Cancer Market Outlook to 2015: Competitive Landscape, Market Size, Pipeline Analysis, and Growth Opportunities

 

The report provides epidemiological analysis, and forecasts prevalence of the major cancer indications turning 2009-2015, including lung, breast, colorectal, and ovarian cancer markets. Also included are detailed analyses of the clinically differentiated products in the cancer pipeline by indication, and sales forecasts for key R&D pipeline products in the global cancer market….

$3835.00

Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion

 

GPCRs are being actively pursued as a target class for developing new therapeutics for various indications. This report discusses the developments in targeting selected, recently deorphaned GPCRs….

$3835.00

OTC Opportunities in Europe, US and Japan: Key Trends, Leading Players and Future Rx-OTC Switching

 

The developed OTC markets in US and UK, are heavily reliant on the prescription (Rx)-to-OTC switching of new-generation products as a means of generating growth. Switching also plays an important role for less-developed markets, such as France, Spain, Italy and Japan, although these countries are currently playing ‘catch-up’ with their developed peers….

$3835.00

Opportunities in Non-Surgical Bio-Implants: Injectable Biomaterials, Applications, and Leading Players

 

The report details the major players, market opportunities, and emerging sectors that are changing the landscape of injectable treatments and major applications in cosmetic dermatology and orthopedics. It provides insights into potential high-growth prospects for novel subcutaneous, intradermal, and intra-articular products, as well as novel matrix formulations for tissue and bone regeneration….

$3835.00

Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates

 

This report explores over 70 new proprietary technologies, licensing deals, and intellectual property positions.

 

Scope

 

Challenges and benefits of therapeutic vaccination….

$3835.00

Advances in Imaging Biomarkers: Innovative Technologies, Applications in R&D and Clinical Practice, Informatics and Regulatory Requirements

 

This report discusses advances in key technologies, the use of imaging biomarkers in drug discovery, as well as development and current use in clinical practice. It also outlines key collaborative initiatives in standardizing imaging technologies and informatics, as well as improving quantification and qualification without which the vision will not be realized….

$3835.00

Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging Technologies and New Therapeutic Candidates

This report examines leading pharmaceutical companies involvement in developing monoclonal antibody-based drugs internally and the recent M&A activity. More than 80 current and emerging technologies are analyzed….

$3835.00

Future of Biologicals: Market Overview, Innovations and Company Profiles

 

This report analyzes the strengths and limitations of the biopharma marketplace, important research avenues being pursued, and an overview of recent R&D developments.

 

This report also provides assessment of the contribution of biopharma to the management of major diseases, identifies possible avenues for new product development, and examines national and regional markets in terms of comparative importance and developing opportunities….

$3835.00

Innovations in Injectables: Current and Emerging Technologies to Improve Drug Delivery

 

This report evaluates the current and evolving technologies used for injectable drug delivery, key therapeutic areas, as well as barriers and driving forces. Leading and emerging companies are analyzed according to the technology type, and new product pipeline….

$3835.00

Cardiovascular Market Outlook to 2015

 

This report provides comprehensive coverage of the cardiovascular market, including disease overview and detailed epidemiological analyses of the major indications. The report contains a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecasts, and competitive landscape for the major players….

$3835.00

Enzymes in Drug Manufacturing

 

Introduction

 

This report examines the benefits and challenges of implementing enzymatic steps in pharmaceutical manufacturing. It covers why enzymes are central to green chemistry and industrial biotechnology….

$3835.00

The Hepatitis Market Outlook to 2016

 

Introduction

 

This report provides comprehensive coverage of the hepatitis market, incorporating a detailed epidemiological analysis. The report analyzes current leading brands, and profiles leading players in the hetpatitis market….

$3835.00

Vaccines in Latin America: Opportunities in Brazil, Mexico and Argentina

 

Over the past decade, vaccines have resurfaced as an attractive commercial proposition for Pharma. The developed world has been the initial focus of vaccine makers due to the better healthcare infrastructure and higher price levels….

$3800.00

Pharmaceutical Industry Infrastructure Overview

 

Introduction

Pharma companies face a number of resistors to profit growth including the looming patent cliff causing a significant slowing in branded sales, coupled with ongoing R&D challenges. Pharma companies are therefore taking by boosting performance through enhancing operating profit through a combination of operating margin and sales growth.

$3800.00

Healthcare System and Drug Regulatory Overview

 

Introduction

Healthcare expenditure is growing fast in all markets, driven by aging populations, a growing prevalence of chronic diseases, expanding government healthcare coverage, use of expensive drugs. Also, as a result of the economic downturn, healthcare funding is under increased scrutiny by governments in developed markets looking to pay down their debts.

$3800.00

Biosimilar Market Overview

 

Introduction Biosimilars were estimated to have generated approximately $200m in sales during the twelve months to March 2010. Going forward, with branded biologics worth $55bn set to face patent expiry between 2011 and 2015, this presents a major opportunity for companies looking to enter the biosimilars market.

$3800.00

HCV – New Market Entrants are Changing Corporate Landscape

 

Introduction

The recent FDA approval of Vertex’s Incivek/Incivo (telaprevir) and Merck’s Victrelis (boceprevir) has heralded a new era in the treatment of hepatitis C (HCV). These agents are also changing the HCV corporate landscape by paving the way for companies that traditionally do not have a presence in HCV to develop the next generation small molecule antivirals.

$3800.00

HIV in Emerging Markets (Brazil, Russia, India): Growing Need for Second and Third Line Therapies

 

Introduction

Faced with limited growth opportunities in western markets, HIV drug developers are looking to expand into emerging markets, marked by a higher disease burden and greater medical unmet need. Efforts to improve treatment coverage coupled with a growing affluent middle class and private sector have turned countries like Brazil, Russia or India into a promising commercial opportunity.

$3800.00

Generics Market Overview

 

Introduction

The combined generics market size is valued at approximately $77bn in the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), the BRIC markets (Brazil, Russia, India, and China), and Australia combined. With branded pharma set to lose approximately $100bn in sales due to the patent cliff, this presents a significant opportunity for generics players during 2011–15.

$3800.00

AstraZeneca: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of AstraZeneca, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market.

Contains 97 pages and 8 tables

 

 

$1900.00

Bristol-Myers Squibb: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of Bristol-Myers Squibb, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market.

Contains 88 pages and 20 tables

 

 

$1900.00

GlaxoSmithKline: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of GlaxoSmithKline, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market.

Contains 149 pages and 13 tables

 

 

$1900.00

Johnson & Johnson: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of Johnson & Johnson, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market.

Contains 103 pages and 8 tables

 

 

$1900.00

Merck: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of Merck, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market.

Contains 99 pages and 8 tables

 

 

$1900.00

Novartis: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of Novartis, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market.

Contains 140 pages and 11 tables

 

 

$1900.00

Pfizer: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of Pfizer, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market.

Contains 117 pages and 7 tables

 

 

$1900.00

Roche: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of Roche, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market.

Contains 112 pages and 11 tables

 

 

$1900.00

Sanofi-Aventis: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of Sanofi-Aventis, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market.

Contains 97 pages and 8 tables

 

 

$1900.00

Wyeth: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of Wyeth, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market.

Contains 65 pages and 7 tables

 

 

$1900.00

Eli Lilly: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of Eli Lilly, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market Contains 65 pages and 7 tables.

$1900.00

Abbott: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

 

A strategic assessment of Abbott, one of the world’s leading pharmaceutical companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global pharmaceutical market.

Contains 90 pages and 8 tables

$1900.00

Pharmaceutical Key Trends: Socio-Demographic and Economic Overview

 

Introduction

Aging populations, the growing prevalence of chronic disease, greater use of expensive treatments, and expanding public healthcare coverage in markets such as the US are stretching existing healthcare resources. Healthcare payers are also feeling the impact of the global economic downturn through reduced funding via taxation as a result of rising unemployment.

$1900.00

Prescription Pharmaceutical Sales Overview

 

Introduction

Pharma is set to loose approximately $108 billion in sales due to the patent cliff and resultant generic erosion of branded sales during 2010–15, while the industry is also feeling the affect of the recent global economic downturn. In response, the industry is implementing a number of strategies to drive sales and profitability going forward: product innovation, diversification and cost-containment.

$1900.00

Key Pharmaceutical Industry Strategic Trends

 

Introduction

A number of factors have and will continue to impact pharmaceutical sales and profits going forward. As a result of rising healthcare costs, healthcare budgets are being stretched….

$1900.00

The 2011 Global Pharmaceutical Market Dynamics and Trends Through 2016

 

A 25-page worldwide strategic overview of the pharmaceutical market, including:

Sales forecast for major product segments: ethical, OTC, generics.

Sales forecast for key geographic regions: North America, Europe, Japan, Latin America….

$1850.00

The 2011 Leading Pharmaceutical Companies Strategic Directions

 

For each company, the report provides insightful strategic assessments, including:

Major strengths and weaknesses.

Business, new product development, and marketing objectives and strategies….

$1850.00

The 2011 Leading Pharmaceutical Companies Financial Analyses

 

Each company’s analysis provides:

U.S….

$1850.00

The 2011 Leading Pharmaceutical Companies R&D Expenditures and Major Programs

 

For each company, the report provides:

Annual R&D budget.

Research facilities and staff….

$1850.00

The 2011 Leading Pharmaceutical Companies Collaborative Arrangements

 

For each company, the report analyzes:

Major joint venture, distribution, OEM, and licensing partners, both industrial and academic.

Terms of collaborative agreements and specific products involved.

The companies analyzed in the report:

 

$1850.00

The 2011 Leading Pharmaceutical Companies Business Organizations and Senior Management Profiles

 

For each company, the report provides:

History of the company’s pharmaceutical business evolution, which is important to understanding the corporate culture, management mentality, and strategies.

Most recent M&A activity and significant organizational changes….

$1850.00

The 2011 Leading Pharmaceutical Companies Technological Know-How

 

For each company, the report analyzes:

Internally developed and acquired technologies, processes, and related capabilities.

Know-how in biotechnology and other pertinent fields….

$1850.00

The 2011 Leading Pharmaceutical Companies Product Portfolio Analyses

 

For each company, the analyses present:

Extensive review of major ethical, OTC, and generic drugs.

Most recent new drug introductions and indications.

$1850.00

The 2011 Leading Pharmaceutical Companies Marketing Tactics

 

For each company, the analysis presents:

Sales force in the U.S….

$1850.00

The 2011 Leading Pharmaceutical Companies Comparative Analysis

 

This report ranks the world’s major pharmaceutical companies according to the following criteria:

Sales and market shares.

Operating profit and margins….

$850.00

To order sections of the reports, contact  Dr.Zadorin Eugene, PhD